| SEC | Form | 4 |
|-----|------|---|
|-----|------|---|

П

### FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL          |           |  |  |  |  |  |  |  |  |
|-----------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:           | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average bur | den       |  |  |  |  |  |  |  |  |
| h                     | 0.5       |  |  |  |  |  |  |  |  |

| hours per response: | 0.5 |
|---------------------|-----|
|                     |     |
|                     |     |

| I. Name and Address of Reporting Feison   |         | 1            | 2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>SANGAMO BIOSCIENCES INC</u> [SGMO] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director 10% Owner |  |                       |  |  |  |
|---|---------|--------------|--|--|--|-----------------------|--|--|--|
| (Last) (First) (Middle)<br>C/O SANGAMO BIOSCIENCES INC.,<br>POINT RICHMOND TECH CNTR, 501 CANAL<br>BLVD |         | INC.,        | 3. Date of Earliest Transaction (Month/Day/Year)<br>09/05/2014                           | Х  | Officer (give title<br>below)<br>VP, Therapeutic Dev.            | Other (specify below) |  |  |  |
|   |         | R, 501 CANAL | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                 | 6. Indiv<br>Line)  | ividual or Joint/Group Filing (Check Applicable                  |                       |  |  |  |
| (Street)<br>RICHMOND  | СА      | 94804        |  | X  | Form filed by One Reporti<br>Form filed by More than C<br>Person | 5                     |  |  |  |
| (City)  | (State) | (Zip)        |  |  |  |                       |  |  |  |

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr. |   | 4. Securities<br>Disposed Of |               |                                 | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-----------------------------|---|------------------------------|---------------|---------------------------------|---|---|---|
|                                 |  |   | Code                        | v | Amount                       | (A) or<br>(D) | Price                           | Transaction(s)<br>(Instr. 3 and 4)  |   | (1150. 4)   |
| Common Stock                    | 09/05/2014                                 |   | М                           |   | 15,000                       | A             | \$4.11                          | 111,579 <sup>(2)</sup>  | D   |   |
| Common Stock                    | 09/05/2014                                 |   | <b>S</b> <sup>(1)</sup>     |   | 15,000                       | D             | <b>\$12.2048</b> <sup>(3)</sup> | 96,579 <sup>(2)</sup>   | D   |   |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of  |        | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|-----|--------|--|--------------------|---|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A) | (D)    | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Employee<br>Stock<br>Option<br>(Right to<br>Buy)    | \$4.11  | 09/05/2014                                 |   | М                            |   |     | 15,000 | (4)  | 12/11/2015         | Common<br>Stock   | 15,000                                 | \$0.00  | 21,798   | D  |  |

#### Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2014.

2. Includes 33,333 shares, 23,333 shares, and 23,000 shares subject to restricted stock units granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.05 to \$12.56, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

4. All shares underlying this option are vested and immediately exercisable.

**Remarks:** 

/s/ Florence Tam, attorney-in-

fact

09/05/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.